| pubmed-article:11956051 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11956051 | lifeskim:mentions | umls-concept:C0021289 | lld:lifeskim |
| pubmed-article:11956051 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:11956051 | lifeskim:mentions | umls-concept:C0020542 | lld:lifeskim |
| pubmed-article:11956051 | lifeskim:mentions | umls-concept:C0456261 | lld:lifeskim |
| pubmed-article:11956051 | lifeskim:mentions | umls-concept:C0441994 | lld:lifeskim |
| pubmed-article:11956051 | lifeskim:mentions | umls-concept:C0529793 | lld:lifeskim |
| pubmed-article:11956051 | lifeskim:mentions | umls-concept:C0348016 | lld:lifeskim |
| pubmed-article:11956051 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:11956051 | pubmed:dateCreated | 2002-4-16 | lld:pubmed |
| pubmed-article:11956051 | pubmed:abstractText | Persistent pulmonary hypertension secondary to meconium aspiration syndrome is an important cause of morbidity and mortality in the neonatal population. We investigated the use of the phosphodiesterase-5 inhibitor sildenafil, in its intravenous form, as a pulmonary vasodilator in a model of meconium aspiration syndrome. Pulmonary hypertension was induced in 18 piglets, by endotracheal instillation of human meconium, 6 piglets subsequently received an infusion of intravenous sildenafil for 2 hours, 6 received inhaled nitric oxide for 2 hours, and 6 control animals received no additional intervention. Meconium aspiration increased pulmonary vascular resistance by 70%, and increased oxygenation index by over 100%. Pulmonary vascular resistance remained elevated for the remainder of the study period in control animals. Inhaled nitric oxide reduced the pulmonary vascular resistance by 40% after 2 hours of treatment; intravenous sildenafil completely reversed the increase in pulmonary vascular resistance within 1 hour of commencing the infusion. Neither agent had an effect on systemic hemodynamics. Sildenafil also increased cardiac output by 30%, but while doing so did not adversely influence oxygenation. Intravenous sildenafil is a selective and highly effective pulmonary vasodilator, which is at least as effective as inhaled nitric oxide, in this model of neonatal persistent pulmonary hypertension. | lld:pubmed |
| pubmed-article:11956051 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11956051 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11956051 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:11956051 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11956051 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11956051 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11956051 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11956051 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11956051 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11956051 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11956051 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11956051 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:11956051 | pubmed:issn | 1073-449X | lld:pubmed |
| pubmed-article:11956051 | pubmed:author | pubmed-author:PennyDaniel... | lld:pubmed |
| pubmed-article:11956051 | pubmed:author | pubmed-author:ShekerdemianL... | lld:pubmed |
| pubmed-article:11956051 | pubmed:author | pubmed-author:RavnHanne BHB | lld:pubmed |
| pubmed-article:11956051 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11956051 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:11956051 | pubmed:volume | 165 | lld:pubmed |
| pubmed-article:11956051 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11956051 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11956051 | pubmed:pagination | 1098-102 | lld:pubmed |
| pubmed-article:11956051 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:11956051 | pubmed:meshHeading | pubmed-meshheading:11956051... | lld:pubmed |
| pubmed-article:11956051 | pubmed:meshHeading | pubmed-meshheading:11956051... | lld:pubmed |
| pubmed-article:11956051 | pubmed:meshHeading | pubmed-meshheading:11956051... | lld:pubmed |
| pubmed-article:11956051 | pubmed:meshHeading | pubmed-meshheading:11956051... | lld:pubmed |
| pubmed-article:11956051 | pubmed:meshHeading | pubmed-meshheading:11956051... | lld:pubmed |
| pubmed-article:11956051 | pubmed:meshHeading | pubmed-meshheading:11956051... | lld:pubmed |
| pubmed-article:11956051 | pubmed:meshHeading | pubmed-meshheading:11956051... | lld:pubmed |
| pubmed-article:11956051 | pubmed:meshHeading | pubmed-meshheading:11956051... | lld:pubmed |
| pubmed-article:11956051 | pubmed:meshHeading | pubmed-meshheading:11956051... | lld:pubmed |
| pubmed-article:11956051 | pubmed:meshHeading | pubmed-meshheading:11956051... | lld:pubmed |
| pubmed-article:11956051 | pubmed:meshHeading | pubmed-meshheading:11956051... | lld:pubmed |
| pubmed-article:11956051 | pubmed:meshHeading | pubmed-meshheading:11956051... | lld:pubmed |
| pubmed-article:11956051 | pubmed:meshHeading | pubmed-meshheading:11956051... | lld:pubmed |
| pubmed-article:11956051 | pubmed:meshHeading | pubmed-meshheading:11956051... | lld:pubmed |
| pubmed-article:11956051 | pubmed:meshHeading | pubmed-meshheading:11956051... | lld:pubmed |
| pubmed-article:11956051 | pubmed:meshHeading | pubmed-meshheading:11956051... | lld:pubmed |
| pubmed-article:11956051 | pubmed:meshHeading | pubmed-meshheading:11956051... | lld:pubmed |
| pubmed-article:11956051 | pubmed:meshHeading | pubmed-meshheading:11956051... | lld:pubmed |
| pubmed-article:11956051 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:11956051 | pubmed:articleTitle | Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. | lld:pubmed |
| pubmed-article:11956051 | pubmed:affiliation | Department of Cardiac Intensive Care, Great Ormond Street Hospital, London, United Kingdom. shekel@cryptic.rch.unimelb.edu.au | lld:pubmed |
| pubmed-article:11956051 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11956051 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11956051 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11956051 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11956051 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11956051 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11956051 | lld:pubmed |
